NextCure share price logo

NextCure

NASDAQ: NXTC

$5.86

-0.12

(-2.01%)

Live

as on

NextCure Stock Performance

as on November 13, 2026 at 6:06 am IST

  • Day's Low

    $5.37
    $5.86
    downward going graph

    8.36%

    Downside

  • 52 Week's Low

    52 Week's High

    $1.55
    $15.74
    downward going graph

    73.55%

    Downside

    168.60%

    Upside

    downward going graph

NextCure share price movements today

Previous Close
$5.98
Open
$5.62
Volume
68.1K
Market Cap
$27.4M
Day's Low - High
$5.37 - $5.86
52 Week Low - High
$1.55 - $15.74

NextCure Historical Returns

1 Month Return
-9.94 %
3 Month Return
-26.81 %
1 Year Return
-35.63 %
3 Year Return
-55.11 %
5 Year Return
-92.25 %

NextCure Stock Fundamentals & Key Indicators

Check NextCure market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$27.4M

EPS (TTM)

-8.65

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-0.69

Industry PE ratio

-2.55

PEG Ratio

-0.01

EBITDA

-40.0M

Revenue (TTM)

-

Profit Margin

0.00%

Return On Equity TTM

-206.63%

NextCure vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of NextCure with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
NextCure image
NextCure
Buy$27.4M-92.25%-0.690.00%0.00%
Moderna image
Moderna
Neutral$101.5B7.57%-35.4828.00%0.00%
BeOne Medicines image
BeOne Medicines
StrongBuy$48.4BNA68.2588.39%0.00%
Vertex Pharmaceuticals image
Vertex Pharmaceuticals
StrongBuy$138.9B192.08%34.9985.57%0.00%
Regeneron image
Regeneron
Buy$94.7B52.00%19.5185.77%0.40%

Stock Returns calculator for NextCure Stock including INR - Dollar returns

The NextCure stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

NextCure investment value today

Current value as on today

₹66,959

Returns

-₹33,041

(-33.04%)

Returns from NextCure Stock

-₹36,921 (-36.92%)

Dollar Impact

₹3,881 (+3.88%)

Analyst Recommendation on NextCure Stock

Based on 10 analysts

BUY

80.00%

Buy

20.00%

Hold

0.00%

Sell

Based on 10 analysts, 80% of analysts recommend a 'BUY' rating for NextCure. Average target price of $20

NextCure Share Price Target

Get share price movements and forecasts by analysts on NextCure.

What analysts predicted

70.7%UPSIDE

Target Price

$20

Current Price

$5.86

Analyzed by

10 Analysts

Target

$20.00

NextCure target price $20, a slight upside of 70.7% compared to current price of $5.86. According to 10 analysts rating.

Indian Investors' Interest in NextCure Stock

Search interest for NextCure Stock has decreased by -60% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-60% versus previous 30 day period

NextCure Quarterly Profit & Loss

All numbers in Millions USD

Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Total Revenue
-
-
-
-
-
-
-
-
-
-
Gross Profit
0
-
-
-
-
-
-
0
-
-
Operating Income
-16
-12
-12
-11
-27
-8
-9
-10
-15
-6
EBITDA
-14
-10
-10
-10
-26
-8
-9
-9
-14
-6
Interest Expense
-
-
-
-
-
-
-
-
-
-
Depreciation
0
0
0
0
0
0
0
0
0
-
Income Before Tax
-15
-11
-11
-10
-26
-8
-9
-9
-14
-6
Income Tax Expense
-
-
-
-
-
-
-
-
-
-
Net Income
-15
-11
-11
-10
-26
-8
-9
-9
-14
-6
Net Profit Margin
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%

NextCure Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
-
-
6
22
-
-
-
-
-
Gross Profit
0
-1
-27
-24
-
-
-
-2
-2
Operating Income
-15
-23
-37
-41
-70
-75
-67
-59
-57
EBITDA
-14
-21
-34
-37
-65
-70
-59
-54
-53
Interest Expense
-
-
0
0
0
-
-
-
-
Depreciation
0
1
2
3
4
4
3
2
2
Income Before Tax
-15
-22
-33
-36
-69
-74
-62
-55
-55
Income Tax Expense
-
-
-
-
-
-
-
-
-
Net Income
-15
-22
-33
-36
-69
-74
-62
-55
-55
Net Profit Margin
0.00%
0.00%
-439.09%
-108.03%
0.00%
0.00%
0.00%
0.00%
0.00%

NextCure Quarterly Cash Flow

All numbers in Millions USD

Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Net Income
-15
-11
-11
-10
-26
-8
-9
-9
-14
-6
Operating Cash Flow
-9
-11
-6
-12
-22
-6
-7
-13
-9
-12
Investing Cash Flow
12
18
6
7
3
8
6
1
9
5
Financing Cash Flow
0
0
0
-
2
-
20
1
0
0
Change in Cash
2
6
0
-5
-16
2
18
-10
0
-6

NextCure Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-15
-22
-33
-36
-69
-74
-62
-55
-55
Operating Cash Flow
-12
7
-35
-44
-57
-53
-52
-40
-49
Investing Cash Flow
-8
-3
-303
43
36
67
39
55
25
Financing Cash Flow
24
121
243
-1
-3
0
0
0
22
Change in Cash
3
126
-96
-2
-23
14
-13
14
-1

Global Institutional Holdings in NextCure

Check out the Institutions with significant holdings in NextCure.

Funds
Holdings
ADAR1 Capital Management, LLC
16.12%
Simcere Zaiming, Inc.
6.74%
Delaware Group Equity Funds IV
3.82%
VANGUARD INDEX FUNDS
3.43%
Vanguard
3.43%
See all

NextCure News & Key Events

  • img

    Today's Timeline - 14 July

    Tue, 03:30 PM

    -

    NextCure announces merger with Avere Therapeutics to accelerate AVR-001 development, expected to close in the second half of 2026.

    Tue, 11:39 PM

    -

    NextCure shares surge 198.63% to $6.51 following merger announcement and financing details.

Insights on NextCure

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 7 days, NXTC stock has moved up by 16.8%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 831.1% return, outperforming this stock by 866.7%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Moderna, Inc. Common Stock has given 255.0% return, outperforming this stock by 310.1%

About NextCure

NextCure, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative immunotherapies. Its core mission is to combat cancer and various other immune-related conditions by reactivating normal immune system function. The company's leading investigational compound, NC318, is currently in Phase II clinical trials, focusing on the treatment of advanced or metastatic solid tumors. Additionally, NextCure is progressing NC410 through Phase I studies; this novel immunomedicine is engineered to counteract immune suppression mediated by Leukocyte-Associated Immunoglobulin-like Receptor 1 (LAIR-1). Another asset, NC762, is an immunotherapeutic designed to target the human B7 homolog 4 protein (B7-H4). Furthermore, NC525, a distinct LAIR-1 antibody, is undergoing preclinical assessment for its potential efficacy against acute myeloid leukemia, specifically targeting blast cells and leukemic stem cells. Beyond these specific pipeline candidates, NextCure's broader research and development efforts encompass the preclinical evaluation of other promising immunomodulatory antibodies and molecules. The company operates under a licensing agreement with Yale University. NextCure, Inc. was established in 2015 and maintains its corporate headquarters in Beltsville, Maryland.
OrganisationNextCure
Headquarters2850 Quarry Lake Drive, Beltsville, MD, 21209, US
IndustryBiotechnology
CEOMichael S. Richman

Key Management of NextCure

Name

Title

Mr. Michael S. Richman MSBA

Co-Founder, CEO, President & Director

Dr. Timothy Mayer Ph.D.

Chief Operating Officer

Dr. Lieping Chen M.D., Ph.D.

Co-Founder & Chairman of Scientific Advisory Board

Mr. Steven P. Cobourn CPA

Chief Financial Officer

Mr. Kevin G. Shaw

Senior VP & General Counsel

Mr. Sourav Kundu Ph.D.

Senior Vice President of Development & Manufacturing

Dr. Sebastien Maloveste Ph.D.

Senior Vice President of Business Development

FAQs

What is NextCure share price today?

NextCure share price today is $5.86 as on . NextCure share today touched a day high of $5.86 and a low of $5.37.

What is the 52 week high and 52 week low for NextCure share?

NextCure share touched a 52 week high of $15.74 on and a 52 week low of $1.55 on . NextCure stock price today i.e. is trending at $5.86,which is 62.77% down from its 52 week high and 278.06% up from its 52 week low.

What is NextCure's market capitalisation today?

NextCure market capitalisation is $0.00T as on .

How to invest in NextCure Stock (NXTC) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for NextCure on INDmoney app. Click on Buy button.

What is the minimum amount required to buy NextCure Stock (NXTC) from India?

Indian investors can start investing in NextCure (NXTC) shares with as little as ₹94.04000091552734 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹940.40 in NextCure stock (as per the Rupee-Dollar exchange rate as on ). Based on NextCure share’s latest price of $5.86 as on November 13, 2026 at 12:36 am IST, you will get 1.7065 shares of NextCure. Learn more about fractional shares .

What are the returns that NextCure has given to Indian investors in the last 5 years?

NextCure stock has given -92.25% share price returns and 26.34% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?